MET基因高表达的非小细胞肺癌能从METMAB获益

50%的非小细胞肺癌存在MET高表达，罗氏2期临床试验，137人服用METMAB，高表达者和低表达者各占一半，METMAB比较安慰剂联合特罗凯，无进展生存期从1.5个月延长至2.9个月；总生存期由3.8个月延长至12.6个月。正在进行三期临床试验


Results from the study of 137 patients suggest the drug could be a major breakthrough in extending the lives of this sub-group of patients with non small cell lung cancer (NSCLC).

Around 50% of NSCLC patients are high Met, meaning that many could benefit from the drug.

Met is a receptor, expressed on the surface of some cells, which is thought to play a role in numerous cancers, including lung cancer. By blocking the action of Met, the drug inhibits the growth, replication and spread of the tumour.

High Met patients benefited greatly from the drug, showing an average doubling of their Progression Free Survival from 1.5 months to 2.9 months.

Most exciting of all, the drug tripled the length of overall survival in these patients, from 3.8 months to 12.6 months. This was, however, only a secondary endpoint of the study, and will require larger trials to back up the findings.

High Met lung cancer patients currently have a particularly poor prognosis, but if the drug is able to replicate the results in larger trials, these patients could see their prognosis become better than other NSCLC patients.

As with other targeted cancer therapies, patients must have a diagnostic test to establish if they have a high or low Met tumour.

“The unique design of MetMab and the development of a companion diagnostic test allowed us to target a specific pathway that may be driving cancer growth,” said Hal Barron, chief medical officer and head, global product development. “These results support further investigation of MetMab as a potential personalised medicine for people with lung cancer and we plan to start a phase III study later this year.”

In contrast to patients with high Met tumours, those with low Met tumours on the trial actually fared worse with the drug than those who did not receive it.

When all the results from the trials’ patients with high and low Met expression were combined, the MetMab and Tarceva combination did not show a statistically significant improvement in PFS compared to Tarceva alone, confirming the drug’s specific action on the Met marker.

The study results will be presented in greater detail at the American Society for Clinical Oncology (ASCO) congress in Chicago, which begins on 4 June.

xl-184应该是和它类似的药，疗效应该差不多

从137名患者的研究结果表明这个小组与非小细胞肺癌（NSCLC）患者的生命延长的药物可能是一个重大突破。

非小细胞肺癌患者中，大约有50％是高满足，这意味着，许多可以从药物中受益。

蛋氨酸是一种受体，某些细胞的表面，这被认为是发挥的作用，在许多癌症，包括肺癌表达。通过阻止会见行动，可抑制肿瘤的生长，复制和传播。

高会见患者大大受益于药物，显示了他们的无进展生存期平均1.5个月至2.9个月增加一倍。

而最令人兴奋的的是，药物的三倍，在这些患者的总生存期的长度，从3.8个月至12.6个月。然而，这只是一个研究的次要终点，将需要更大的试验，以备份的结果。

高MET肺癌患者目前有一个特别差的预后，但如果该药物是能够复制在较大的试验结果，这些病人可以看到他们的预后优于其他非小细胞肺癌患者。

至于与其他有针对性的癌症疗法，患者必须有一个诊断测试，以确定他们是否有高或低的气象肿瘤。

“，”哈尔说，首席医疗官和头部，全球产品开发巴伦MetMab独特的设计和同伴诊断测试的发展，使我们能够针对特定的途径，可能驾驶癌细胞生长。 “这些结果支持进一步MetMab调查，作为一个潜在的个性化药物为肺癌的人，我们计划在今年晚些时候开始第三阶段的研究。”

在对比高会见肿瘤，低会见审判肿瘤的实际表现比那些谁没有收到药物差的患者。

当所有试验的患者有高有低Met表达的结果相结合，MetMab和特罗凯的联合并不会显示在加油站相比，特罗凯单独统计上的显著改善，确认药物的具体行动上的气象标志。

这项研究结果将提交临床肿瘤学会（ASCO）在芝加哥举行的大会，6月4日开始在美国社会在更大的详细。

那么XL184和特罗凯联用不会增加效果咯

http://www.ccmtv.cn/Conference/ASCO2011/2011720175011.shtml

在受试的137人中，128人可评估疗效。在128人中，不吸烟者有13人，其中10人为MET高表达。我妈不抽烟，MET阳性的机会还是比较大的

Good try ,个人感觉翻译的不是特别准确。已经不错

对于骨转，184耐药这个是个好选择，脊椎转移184耐药了，可能会避免危险脊椎放疗。